AstraZeneca PLC News
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
see moreAstraZeneca PLC Market News
6d
AZN Exits Nasdaq-100; NYSE Listing & AI Deal Alert
- AstraZeneca (AZN) was removed from the Nasdaq‑100 on Jan 20, 2026, is shifting its U.S. listing to the NYSE in early February, and has acquired Modella AI to speed oncology R&D—moves that change index-driven flows, trading composition, and long-term strategy.
13d
AstraZeneca Loses Nasdaq-100 Spot; What's Next
AstraZeneca's switch from Nasdaq ADSs to NYSE ordinary shares and its removal from the Nasdaq‑100 triggered heavy trading and a sharp share drop. This article explains the mechanics of the transition, immediate index-driven flows, near-term risks ahead of February earnings, and longer-term strategic implications for AZN investors.
20d
AstraZeneca Nasdaq Exit and ENHERTU FDA Decisions
AstraZeneca faces removal from the Nasdaq-100 on Jan 20, 2026, days before a critical FDA decision (Jan 23, 2026) on an ENHERTU + pertuzumab first-line indication for HER2‑positive metastatic breast cancer. The near-term index-driven outflows could pressure AZN shares, while a favorable FDA outcome would be a meaningful commercial and sentiment catalyst.
27d
AstraZeneca: Onshoring Gains, Pricing Risks 2026.
Recent coverage shows AstraZeneca (AZN) benefiting from U.S. onshoring and strong oncology sales while facing pricing scrutiny in Europe. Key operational moves and discrete regulatory wins propelled sentiment this week, even as semaglutide pricing and policy risk temper the outlook.
01 Jan at 00:37
AZN: FDA Nod, Oncology Sales Rise, Maryland Update
AstraZeneca (AZN) strengthened its commercial and operational footing with recent FDA approvals for Dato‑DXd (Datroway) and an expanded indication for Calquence, a robust oncology sales quarter, and a $2 billion Maryland manufacturing expansion. These developments boost near-term revenue potential and long-term capacity for biologics and rare-disease therapies.
25 Dec at 00:37
AstraZeneca Weak Volume, Missing U.S. Pricing Pact
AstraZeneca (AZN) slipped in thin holiday trading after hitting a recent 52-week high; analysts remain broadly positive but AZN was excluded from a major U.S. drug‑pricing deal, a development with nuanced implications for near‑term policy risk and investor positioning.
18 Dec at 00:37
AstraZeneca BofA Upgrade Spurs Q3 Profit Surge Up
AstraZeneca (AZN) climbed after Bank of America raised its 12‑month price target to $108.50, supported by a 77% jump in Q3 profit and upcoming oncology readouts (AVANZAR, SERENA‑4). Elevated trading volumes and analyst upgrades signal growing investor focus on AZN’s pipeline catalysts.